Tolerability and effectiveness of sofosbuvir and simeprevir in the posttransplant setting: systematic review and meta-analysis

BMJ Open Gastroenterology

Volumn 3, Issue 1, 2016, Pages

  Nguyen, Nghia H ^a   Yee, Brittany E ^a   Chang, Christine ^b   Jin, Minjuan ^c   Lutchman, Glen ^b   Lim, Joseph K ^d   Nguyen, Mindie H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c ZHEJIANG UNIVERSITY   (China)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EFFECT SIZE; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HUMAN; INSOMNIA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDLINE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; POSTOPERATIVE PERIOD; PRURITUS; RASH; STATISTICAL ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 85038895504     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2015-000066     Document Type: Article

References (30)

1. Wiesner RH, Sorrell M, Villamil F. International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplan 2003;9:S1-9.
2. Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973.
3. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815.
4. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274.
5. Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389.
6. Burton JR Jr, O'Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014;61:508.
7. Nair SP. Protease inhibitor therapy post-liver transplantation in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) 2013;9:388.
8. Faisal N, Yoshida EM, Bilodeau M, et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014;13:525.
9. Coilly A, Roche B, Duclos-Vallée JC, et al. Management of HCV transplant patients with triple therapy. Liver Int 2014;34(Suppl 1):46.
10. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756.
11. Suliman I, Pozza R, Kady Y, et al. The Combination of Simeprevir and Sofosbuvir for the Treatment of HCV Infection in Patients Post Liver Transplant With Significant Fibrosis [abstract]. Hepatology 2014;60(Suppl 1):545A.
12. Ripper SJ, Holt EW, Cooper S, et al. Simeprevir plus Sofosbuvir for Patients with Recurrence of Genotype 1 Hepatitis C Infection after Liver Transplantation [abstract]. Hepatology 2014;60(Suppl 1):684A.
13. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015;61:1880-6.
14. Nair SP, Dbouk N, Lingala S, et al. Safety and Efficacy of Simeprevir, Sofosbuvir, and Ribavirin Combination Therapy in Liver Transplant Recipients with Severe Recurrent HCV [abstract]. Hepatology 2014;60(Suppl 1):681A.
15. Lutchman GA, Nguyen NH, Hsiao TI, et al. Safety and effectiveness of sofobsuvir (SOF) in combination with simeprevir (SIM) or ribavirin (RBV) for the treatment of hepatitis C virus (HCV) recurrence after liver transplant (LT) [abstract]. Hepatology 2014;60 (Suppl 1):670A.
16. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. Liver Transpl 2015;21:823-30.
17. Gordon FD, Kosinski AL, Coombs SJ, et al. Sofosbuvir + simeprevir is safe in liver transplant recipients [abstract]. Hepatology 2014;60 (Suppl 1):543A.
18. Ford RM, Pillai A, Cheng N, et al. Post-liver transplant treatment of hepatitis c with a combination of sofosbuvir, simeprevir, +/-ribavirin at a high volume academic transplant center [abstract]. Hepatology 2014;60(Suppl 1):701A.
19. Crittenden N, Davis EG, Marsano LS, et al. Single center experience with simeprevir/sofosbuvir combination therapy for recurrent hepatitis C virus infection in liver transplant recipients [abstract]. Hepatology 2014;60(Suppl 1):700A.
20. Reddy KR, Everson GT. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. Hepatology 2013;58:1181.
21. Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int 2015;35:2442-7.
22. Price JC, Terrault NA. Treatment of hepatitis C in liver transplant patients: interferon OUT, direct antiviral combos IN. Liver Transpl 2015;21:423-34.
23. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108.
24. Charlton M, Everson GT, Flamm SL, Jr, et al, SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.
25. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19.
26. BVBA JID. Efficacy and safety study of simeprevir in combination with sofosbuvir in participants with chronic hepatitis C virus infection without cirrhosis. Bethesda MD: National Library of Medicine (US): ClinicalTrials.gov [Internet], 2014.
27. BVBA JID. Efficacy and safety study of simeprevir in combination with sofosbuvir in participants with genotype 1 chronic hepatitis C virus infection and cirrhosis. Bethesda MD: National Library of Medicine (US): ClinicalTrials.gov [Internet], 2014.
28. SC Liver Research Consortium LJ, LP. SMV + SOF with/without RBV for IFN-II patients with CHC. Bethesda MD: National Library of Medicine (US): ClinicalTrials.gov [Internet], 2014.
29. Janssen Scientific Affairs L. An efficacy and safety study of simeprevir and sofosbuvir with and without ribavirin in participants with recurrent genotype 1 hepatitis C Post-Orthotopic liver transplant (GALAXY). Bethesda MD: National Library of Medicine (US): ClinicalTrials.gov [Internet], 2014.
30. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.